Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Allurion Technologies, Inc.

Healthcare US ALUR

6.038USD
0.0005(0.0083%)

Last update at 2026-06-23T20:00:00Z

Day Range

0.550.63
LowHigh

52 Week Range

0.233.42
LowHigh

Fundamentals

  • Previous Close 6.04
  • Market Cap10.95M
  • Volume17694
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-29.17400M
  • Revenue TTM15.23M
  • Revenue Per Share TTM2.02
  • Gross Profit TTM 9.57M
  • Diluted EPS TTM-3.81

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -28.68100M -25.43000M -80.34300M -37.60100M -12.38600M
Minority interest - - - - -
Net income -28.75500M -26.14800M -82.30400M -37.74400M -12.38600M
Selling general administrative 21.35M 28.40M 46.02M 15.37M 8.82M
Selling and marketing expenses 10.80M 25.93M 46.86M 50.41M 27.14M
Gross profit 9.57M 21.50M 41.50M 50.73M 29.19M
Reconciled depreciation 0.98M 1.00M 1.91M 2.00M 0.71M
Ebit -28.68100M -23.16600M -69.77700M -33.17500M -13.05600M
Ebitda -27.69800M -22.16900M -69.03100M -32.28000M -12.34900M
Depreciation and amortization 0.98M 1.00M 0.75M 0.90M 0.71M
Non operating income net other - - - - -
Operating income -30.15700M -50.19800M -79.07800M -32.01000M -12.50100M
Other operating expenses 45.39M 82.31M 132.54M 96.22M 50.74M
Interest expense 0.00000M 2.26M 10.57M 4.43M 3.67M
Tax provision 0.07M 0.72M 0.14M 0.14M 0.00000M
Interest income - - - - -
Net interest income 0.00000M -2.26400M -9.09100M -4.42600M -3.66800M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.07M 0.72M 0.26M 0.14M 3.11M
Total revenue 15.23M 32.11M 53.47M 64.21M 38.24M
Total operating expenses 39.73M 71.70M 120.58M 82.74M 41.69M
Cost of revenue 5.66M 10.61M 11.97M 13.48M 9.05M
Total other income expense net 1.48M 24.77M -1.26500M -5.59100M 0.12M
Discontinued operations - - - - -
Net income from continuing ops -28.75500M -26.14800M -73.77500M -37.74400M -12.38600M
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 15.77M 32.81M 71.71M 51.37M 39.35M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.76M 1.24M 2.41M 2.49M 1.94M
Total liab 92.96M 110.79M 142.20M 122.81M 73.64M
Total stockholder equity -77.18900M -77.97800M -70.48700M -71.43600M -34.28500M
Deferred long term liab - - - - -
Other current liab 6.41M 11.42M 14.59M 15.79M 11.30M
Common stock 0.00600M 0.00300M 0.00500M 0.05M 0.05M
Capital stock 0.00600M 0.00300M 0.00500M 58.05M 58.02M
Retained earnings -250.96200M -222.20700M -212.79900M -132.19200M -94.44800M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 5.41M 15.38M 38.04M 7.68M 25.84M
Cash and equivalents - - - - -
Total current liabilities 38.45M 18.86M 65.42M 75.87M 31.61M
Current deferred revenue - - - - 0.20M
Net debt 23.63M 22.54M 3.82M 51.85M 0.30M
Short term debt 28.47M 0.87M 40.46M 54.27M 24.14M
Short long term debt 28.07M - 38.64M 53.36M 24.14M
Short long term debt total 29.04M 37.92M 41.86M 59.53M 26.14M
Other stockholder equity 168.63M 152.60M 143.01M 2.71M 2.14M
Property plant equipment - - - - -
Total current assets 12.79M 27.16M 64.82M 43.38M 37.33M
Long term investments - - - - -
Net tangible assets - - - - -
Short term investments - - - - -
Net receivables 3.95M 7.13M 18.19M 29.35M 6.83M
Long term debt - 35.71M - 3.10M 2.00M
Inventory 2.67M 3.40M 6.17M 3.87M 2.71M
Accounts payable 3.57M 6.57M 10.38M 5.81M 1.62M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 5.14M -8.37000M -0.70000M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.66M 1.11M 0.12M 2.71M 0.31M
Deferred long term asset charges - - - - -
Non current assets total 2.98M 5.66M 6.90M 7.99M 2.02M
Capital lease obligations 0.97M 2.21M 3.21M 3.07M -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.61100M -1.60600M -1.55000M -0.91200M
Change to liabilities - - - - -
Total cashflows from investing activities - -0.61100M - - -
Net borrowings 0.00000M 0.07M - - -
Total cash from financing activities 18.97M 20.21M 95.99M 30.54M 28.95M
Change to operating activities - - - - -
Net income -28.75500M -26.14800M -80.60700M -37.74400M -12.38600M
Change in cash -9.97600M -22.70300M 30.40M -17.99400M 13.70M
Begin period cash flow 15.72M 38.42M 8.02M 26.02M 12.31M
End period cash flow 5.74M 15.72M 38.42M 8.02M 26.02M
Total cash from operating activities -28.94600M -42.30000M -63.98200M -46.98100M -14.32900M
Issuance of capital stock 18.97M 21.26M - 0.00000M 9.87M
Depreciation 0.98M 1.00M 0.75M 2.00M 0.71M
Other cashflows from investing activities - - - - -
Dividends paid - - - 0.13M -
Change to inventory -0.48600M 0.54M -3.70500M -1.15000M -1.28500M
Change to account receivables 0.84M 8.98M -1.31800M -22.81700M -0.70700M
Sale purchase of stock - - - -776.54322M -
Other cashflows from financing activities 18.97M -1.33100M 95.92M -0.54800M 9.87M
Change to netincome - - - - -
Capital expenditures 0.00000M 0.61M 1.61M 1.55M 0.91M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -7.82400M 1.60M 0.19M -13.78800M -1.27500M
Stock based compensation 3.15M 3.06M 8.36M 0.44M 0.31M
Other non cash items 3.50M -21.80500M 7.33M 0.84M -2.35300M
Free cash flow -28.94600M -42.91100M -65.58800M -48.53100M -15.24100M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ALUR
Allurion Technologies, Inc.		 0.0005 0.0083% 6.04 - 0.83 0.72 - 2.34 -2.1477
ABT
Abbott Laboratories		 0.90 0.99% 91.43 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation		 4.65 1.50% 314.65 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -0.31 0.38% 80.32 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 -0.29 0.64% 45.31 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

View All

Profile

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform offers the Allurion Program, a swallowable and procedure-less intragastric balloon for weight loss, as well as provides access to artificial intelligence-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company operates in Spain, France, Turkey, and internationally. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.

Allurion Technologies, Inc.

11 Huron Drive, Natick, MA, United States, 01760

Key Executives

Name Title Year Born
Dr. Shantanu K. Gaur M.D. Co-Founder, CEO, President, Principal Financial & Accounting Officer and Director 1986
Dr. Samuel G. Levy Co-Founder 1983
Dr. Ram Chuttani M.D. MD, Chief Medical Officer & Founding Partner 1961
Mr. Ojas A. Buch Chief Operating Officer 1973
Mr. Brendan Michael Gibbons J.D. Chief Legal Officer & Corporate Secretary 1976
Mr. Matt Wright Vice President of People NA
Ms. Joyce Johnson Senior Vice President of Regulatory Affairs & Quality Assurance NA
Dr. Shantanu K. Gaur M.D. Co-Founder, CEO, President, Principal Financial & Accounting Officer and Director 1987
Mr. Ojas A. Buch Chief Operating Officer 1974
Mr. Brendan Michael Gibbons J.D. Chief Legal & People Officer and Secretary 1976

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.